SMFM Statement

Coding : Coding Tips Coding : Coding White Papers News Publications & Guidelines Publications & Guidelines : Administrative Publications & Guidelines : Consult Series Publications & Guidelines : Endorsed Partner Pub Publications & Guidelines : Health Policy Publication Publications & Guidelines : Joint Publication Publications & Guidelines : Obstetric Care Consensus Publications & Guidelines : Public/Global Health Publications & Guidelines : SMFM Special Report Publications & Guidelines : SMFM Statement

SMFM Position Statement: Gun violence and pregnancy
SMFM Position Statement: Gun violence and pregnancy

The Society for Maternal-Fetal Medicine acknowledges gun violence as a public health crisis in the United States, with a substantial impact on pregnant and postpartum people. Continue Reading

Date posted04/8/2024


SMFM Position Statement: Access to abortion care
SMFM Position Statement: Access to abortion care

The Society for Maternal-Fetal Medicine supports the right of all individuals to access the full spectrum of reproductive health services, including abortion care. Continue Reading

Date posted04/6/2024


SMFM Position Statement: Extending Medicaid coverage for 12 months postpartum
SMFM Position Statement: Extending Medicaid coverage for 12 months postpartum

Position: The Society for Maternal-Fetal Medicine supports federal and state policies that expand Medicaid eligibility and extend Medicaid coverage through 12 months postpartum to address the maternal morbidity and mortality crisis and improve health equity. Access to coverage is essential to... Continue Reading

Date posted04/6/2024


Operative vaginal delivery: checklists for performance and documentation
Operative vaginal delivery: checklists for performance and documentation

The frequency of operative vaginal delivery has been declining, even though it can be an attractive alternative to cesarean delivery in selected cases. Performance of operative vaginal delivery requires consideration of many indications, contraindications, and prerequisites. Optimal documentation... Continue Reading

Date posted01/1/2024


RhD immune globulin after spontaneous or induced abortion less than 12 weeks of gestation
RhD immune globulin after spontaneous or induced abortion less than 12 weeks of gestation

Abstract: Guidelines for the management of first-trimester spontaneous and induced abortion vary regarding RhD testing and Rho(D) immune globulin administration. These existing guidelines are based on limited data that do not convincingly demonstrate the safety of withholding Rho(D) immune... Continue Reading

Date posted01/1/2024


A report and recommendations of the workshop of the Society for Maternal-Fetal Medicine
A report and recommendations of the workshop of the Society for Maternal-Fetal Medicine

This article is a report of a 2-day workshop, entitled “Social determinants of health and obstetric outcomes,” held during the Society for Maternal-Fetal Medicine 2022 Annual Pregnancy Meeting. Participants’ fields of expertise included obstetrics, pediatrics, epidemiology,... Continue Reading

Date posted12/30/2023


Clinical considerations for the prevention of respiratory syncytial virus disease in infants
Clinical considerations for the prevention of respiratory syncytial virus disease in infants

SMFM Statement Continue Reading

Date posted11/19/2023


Workshop on developing optimal maternal-fetal medicine ultrasound practice
Workshop on developing optimal maternal-fetal medicine ultrasound practice

SMFM Statement Continue Reading

Date posted11/12/2023


Prophylactic low-dose aspirin for preeclampsia prevention—quality metric and improvement
Prophylactic low-dose aspirin for preeclampsia prevention—quality metric and improvement

SMFM Statement Continue Reading

Date posted11/9/2023


Curriculum outline on patient safety and quality for maternal-fetal medicine fellows
Curriculum outline on patient safety and quality for maternal-fetal medicine fellows

SMFM Statement Continue Reading

Date posted11/4/2023


Response to the Food and Drug Administration’s withdrawal of 17-alpha hydroxyprogesterone caproate
Response to the Food and Drug Administration’s withdrawal of 17-alpha hydroxyprogesterone caproate

SMFM Statement Continue Reading

Date posted11/3/2023


Rate of postpartum diabetes screening after pregnancies with gestational diabetes mellitus
Rate of postpartum diabetes screening after pregnancies with gestational diabetes mellitus

SMFM Statement Continue Reading

Date posted11/2/2023